On August 2, the Centers for Medicare & Medicaid Services (CMS) released the Hospital Inpatient Prospective Payment System (IPPS) final rule for fiscal year (FY) 2020. The rule finalizes changes that will affect all U.S. hospitals, including:
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the proposal and will provide more information to members as soon as possible. Based on a preliminary analysis, key provisions in the proposed rule include:
Annual HOPPS Update
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B payment policies, including proposals related to the Quality Payment Program (QPP), online ahead of publication in the Federal Register on August 14.
ASCO recently submitted comments to the Senate Finance Committee hearing, “Medicare Physician Payment Reform After Two Years: Examining MACRA Implementation and the Road Ahead.” The society’s comments focus on ASCO’s efforts to help members implement provisions of the Medicare Access and CHIP Reauthorization Act (MACRA) in their practices and offered ideas for how Congress and the Centers for Medicare & Medicaid Services (CMS) can strengthen MACRA and the Medicare program in the years ahead.
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO urged the agency to protect patient access to necessary cancer care under Medicare Advantage (MA) and Medicare Part D. The comments were submitted in response to proposed changes to MA and Part D aimed at lowering drug prices.
On January 31, ASCO joined more than 60 organizations in requesting the Centers for Medicare & Medicaid Services (CMS) to reverse its recent decision to limit coverage for Next Generation Sequencing (NGS). The organizations expressed concern that the decision will make it harder for patients to access medically necessary and relevant clinical tests, reducing the quality of their cancer treatment and care.
ASCO has been informed that some oncology practices and providers in the Merit-Based Incentive Payment System (MIPS) have received inaccurate payment adjustments as a result of Medicare Part B drug costs incorrectly being included in the adjustments.
Reimbursement cuts for certain oncology specialties. Changes in documentation requirements for certain E&M services. Reduced reimbursement for new Medicare Part B drugs. These are some of the changes coming to the Medicare Physician Fee Schedule and the Quality Payment Program this year. In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis discusses the changes made to the physician fee schedule and the Quality Payment Program, and what this may mean for your oncology practice.
As part of the Trump Administration’s continuing effort to address the cost of prescription drugs, the Centers for Medicare & Medicaid Services (CMS) recently solicited input on a proposed new pilot program to test mechanisms for reducing drug costs. The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.